Mettler-Toledo International Inc (MTD)vsNovartis AG ADR (NVS)
MTD
Mettler-Toledo International Inc
$1,293.52
+1.01%
HEALTHCARE · Cap: $26.56B
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1271% more annual revenue ($56.69B vs $4.13B). NVS leads profitability with a 22.5% profit margin vs 21.9%. MTD appears more attractively valued with a PEG of 2.50. MTD earns a higher WallStSmart Score of 64/100 (C+).
MTD
Buy64
out of 100
Grade: C+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MTD.
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 30 in profit
Keeps 22 of every $100 in revenue as profit
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.5% revenue growth
Weak financial health signals
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : MTD
The strongest argument for MTD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 21.9% and operating margin at 31.2%.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : MTD
The primary concerns for MTD are PEG Ratio, P/E Ratio, Revenue Growth. Debt-to-equity of 164.70 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
MTD carries more volatility with a beta of 1.22 — expect wider price swings.
MTD is growing revenue faster at 4.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MTD scores higher overall (64/100 vs 51/100), backed by strong 21.9% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Mettler-Toledo International Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Mettler Toledo (NYSE: MTD) is a multinational manufacturer of scales and analytical instruments. It is the largest provider of weighing instruments for use in laboratory, industrial, and food retailing applications. The company also provides various analytical instruments, process analytics instruments, and end-of-line inspection systems.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?